DCAT Announces New Board of Directors for 2024
The DCAT organization is pleased to announce the members of its Board of Directors for the 2024 fiscal year (November 1, 2023 to October 31, 2024). The members were interviewed and selected by the organization’s Leadership Development Committee and were approved by Member Company Designated Delegates through balloting over the last several weeks.
EXECUTIVE COMMITTEE: BOARD OF DIRECTORS
Elected as President is Charles Davies, Associate Vice President, Global Sourcing and Procurement at Merck & Co. Inc. Previously, Mr. Davies served as the First Vice President, Second Vice President/Finance Officer, and Third Vice President.
“It is with utmost honor and enthusiasm that I address you today as the newly elected President of our esteemed DCAT Pharmaceutical Trade Organization for the 2024 term. I am deeply grateful for the trust and confidence you have placed in me, and I am committed to serving our industry with dedicated leadership and unwavering passion.”
Read the full statement from Mr. Davies here.
Joining Mr. Davies on the Executive Committee will be:
Donna Gruol of Lone Fox Endeavors LLC., who previously served as Second Vice President/Finance Officer and will now serve as the First Vice President. Kelsey Achenbach of dsm-firmenich, who previously served as the Third Vice President and will now serve as the Second Vice President/Finance Officer. Ken Seufert of JRS Pharma who previously served as a Director was elected as the Third Vice President.
DIRECTORS: BOARD OF DIRECTORS
Re-elected as Directors on the Board are Camran Aslam of AbbVie, Inc., Craig Douglas of Siegfried-USA, LLC, and Courtney Stanton of Bioseutica B.V. Newly elected to the Board are Christopher Conway of Curia and Pierfrancesco Morosini of ICROM.
IMMEDIATE PAST PRESIDENTS: BOARD OF DIRECTORS
Rounding out the eleven-person Board of Directors are the Immediate Past Presidents, Sally Macaluso of Johnson & Johnson and Kerri McCullough Wood of Teva API, Teva Pharmaceuticals.